Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function
https://doi.org/10.21518/2079-701X-2018-19-28-30
Abstract
Treatment of choice of metastatic hormone-dependent breast cancer regardless of age is hormone therapy (HT) even with visceral metastases. Now we have a new class of drugs called inhibitors of cyclin-dependent kinases 4/6, which significantly increase effectiveness of HT and prevent development of resistance to HT. In MONALEESA-7 inhibitor of cyclin-dependent kinases 4/6 ribociclib was studied in combination with ovarian suppression and hormone therapy in young patients with preserved ovarian function, and found no differences in the efficacy and safety of these drugs compared with menopausal patients. Our clinical experience strongly demonstrates the safety and efficacy of ribociclib in combination with HT and ovarian suppression in premenopausal patient with visceral metastases.
About the Authors
S. F. Menshikova
FSAEI HE I.M. Sechenov First Moscow State Medical University оf the Ministry of Health of the Russian Federation (Sechenov University)
Russian Federation
Department of Oncology
Russian Federation
Department of Oncology
M. A. Frolova
FSBI «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation
Russian Federation
Department of Clinical Pharmacology and Chemotherapy
Russian Federation
Department of Clinical Pharmacology and Chemotherapy
E. V. Glazkova
FSBI «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation
Russian Federation
Department of Clinical Pharmacology and Chemotherapy
Russian Federation
Department of Clinical Pharmacology and Chemotherapy
M. B. Stenina
FSBI «N.N. Blokhin National Medical Research Center of Oncology» оf the Ministry of Health of the Russian Federation
Russian Federation
Department of Clinical Pharmacology and Chemotherapy
Russian Federation
Department of Clinical Pharmacology and Chemotherapy
References
1. Tancredi R et al. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature. The Oncologist, 2018, 23(8): 974-981.
2. Cardoso F. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast, 2014 Oct, 23(5): 489-502.
3. Boyle F et al. Hormone receptor positive, HER2 negative metastatic breast cancer: Impact of CDK4/6 inhibitors on the current treatment paradigm. Asia Pac J Clin Oncol, 2018 Oct, 14(Suppl 4): 3-11. doi: 10.1111/ajco.13064.
4. Finn RS, Martin M, Rugo H et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med, 2016, 375: 1925-36.
5. Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med, 2016, 375: 1738–48.
6. Cristofanilli M, Turner NC, Bondarenko I, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormonereceptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016, 17: 425–39.
7. Slamon DJ, Neven P, Chia S, et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol, 2018, 36: 2465-72. JCO2018789909.
8. Tripathy D et al. Ribociclib plus endocrine therapy for premenopausal women with hormonereceptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lanc Onc, 2018 Jul, 19(7): 904–915.
9. Foukakis T. Ribociclib in premenopausal women with advanced breast cancer (Commentary). Lanc Onc, 2018 Jul, 19(7): 850–852.
Review
For citations:
Menshikova SF, Frolova MA, Glazkova EV, Stenina MB. Ribociclib in the first-line therapy for metastatic hormone-dependent HER2-negative breast cancer in patients with intact ovarian function. Meditsinskiy sovet = Medical Council. 2018;(19):28-30. (In Russ.) https://doi.org/10.21518/2079-701X-2018-19-28-30
Views:
1523
Email this article 